<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151671</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS 21541</org_study_id>
    <secondary_id>PHRC/02-10</secondary_id>
    <secondary_id>CIC0203/012</secondary_id>
    <nct_id>NCT00151671</nct_id>
  </id_info>
  <brief_title>Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Prospective, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Oral Immune-Enhancing Nutritional Supplement on Hepatic Function After Liver Resection for Primary or Secondary Cancer on Cirrhosis or Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70%
      of them develop severe complications. These failures are mainly due to hepatic insufficiency.
      Studies have already shown benefits of oral nutritional supplements in ORL, digestive, and
      cardiac surgery. We aimed to ascertain whether this nutritional, immune-enhancing
      supplementation, administered 7 days before and 3 days after surgery, could improve liver
      function and postoperative host defences in patients with liver cancer resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients undergoing hepatic resection for liver cancer (with cirrhosis or fibrosis liver),
      mortality rate can reach 10% and morbidity (ascites, icteria, infections) 70%. These
      complications are mainly due to hepatic insufficiency: surgery leaves a reduced parenchyma,
      with oxidative stress lesions due to reperfusion injury. A good preoperative nutritional
      state has been shown to reduce complications and mortality. This can be amplified by
      preoperative nutrition with supplements containing L-arginin, ω3 polyunsaturated fatty acids,
      and nucleotides which boost immune responses, resistance to infections and liver function
      recovery. In this context, the study randomly assigns 50 patients who were scheduled to
      undergo hepatic resection, to receive either an oral immune-enhancing nutritional supplement
      or a placebo, for the 7 last preoperative and the first 3 postoperative days. The aim of the
      study is to evaluate the effects of this supplementation on liver function, immunity, and
      incidence of infections after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment rate
  </why_stopped>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Factor V at day 3 after surgery</measure>
    <time_frame>day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver regeneration kinetics (bile production at days 1, 3, 5 and 7;factor V, γ-glutathione transferase, α-foetoprotein at days 1, 3, 5, 7, 10 and 30; liver volume at days 10 and 30</measure>
    <time_frame>days 1, 3, 5, 7, 10 and 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological biomarkers</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cirrhosis</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative Oral Nutritional Supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Perioperative Oral Nutritional Supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Impact®</intervention_name>
    <description>Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult over 18 years

          -  Hepatectomy of at least 2 segments

          -  For primary or secondary cancer

          -  With cirrhosis (Child Pugh &lt;8) or liver fibrosis (fibrosis score of 3)

          -  Informed written consent

        Exclusion Criteria:

          -  Pregnancy

          -  Recent weight loss of more than 10% of body weight

          -  Immunological deficiency

          -  Portal or hepatic arterial thrombosis

          -  Biliary duct dilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick Mallédant, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Seguin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim Boudjema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Réanimation Chirurgicale - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Tepaske R, Velthuis H, Oudemans-van Straaten HM, Heisterkamp SH, van Deventer SJ, Ince C, Eÿsman L, Kesecioglu J. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet. 2001 Sep 1;358(9283):696-701.</citation>
    <PMID>11551575</PMID>
  </reference>
  <reference>
    <citation>Senkal M, Zumtobel V, Bauer KH, Marpe B, Wolfram G, Frei A, Eickhoff U, Kemen M. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: a prospective randomized study. Arch Surg. 1999 Dec;134(12):1309-16.</citation>
    <PMID>10593328</PMID>
  </reference>
  <reference>
    <citation>Braga M, Gianotti L, Radaelli G, Vignali A, Mari G, Gentilini O, Di Carlo V. Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. Arch Surg. 1999 Apr;134(4):428-33.</citation>
    <PMID>10199318</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>February 24, 2012</last_update_submitted>
  <last_update_submitted_qc>February 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2012</last_update_posted>
  <responsible_party>
    <name_title>Direction of Clinical Research and Strategy</name_title>
    <organization>Rennes University Hospital</organization>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

